These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34903191)

  • 1. Triplet versus doublet neoadjuvant chemotherapy regimens for locally advanced gastric cancer: a propensity score matching analysis.
    Chen Y; He J; Liu D; Xiao J; Chen X; Tang H; Luo D; Shang C; Lian L; Peng J
    BMC Cancer; 2021 Dec; 21(1):1328. PubMed ID: 34903191
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neoadjuvant therapy with immune checkpoint inhibitors in combination with chemotherapy vs . chemotherapy alone in HER2(-) locally advanced gastric cancer: A propensity score-matched cohort study.
    Xu G; Liu T; Shen J; Guan Q
    Chin Med J (Engl); 2024 Feb; ():. PubMed ID: 38420853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Outcome of Doublet and Triplet Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer.
    Kim JS; Kang SH; Moon HS; Sung JK; Jeong HY; Sul JY
    Korean J Gastroenterol; 2016 Nov; 68(5):245-252. PubMed ID: 27871160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Retrospective Study of Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer.
    Wang Y; He K; Zhou Z; Zhong Y; Li G; Lu J
    Cancer Manag Res; 2020; 12():8491-8496. PubMed ID: 32982442
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prognostic analysis of neoadjuvant chemotherapy for locally advanced gastric cancer with propensity score matching method].
    Peng L; Yang W; Zhang Z; Zhi C; Zhou X; Liu H; Hua Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2018 Oct; 21(10):1148-1153. PubMed ID: 30370514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis.
    Wang T; Li C; Li X; Zhai J; Wang S; Shen L
    Eur J Med Res; 2022 Nov; 27(1):239. PubMed ID: 36352476
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neoadjuvant chemotherapy
    Li Y; Ma FH; Xue LY; Tian YT
    World J Gastroenterol; 2020 Feb; 26(8):818-827. PubMed ID: 32148379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis.
    Kano M; Hayano K; Hayashi H; Hanari N; Gunji H; Toyozumi T; Murakami K; Uesato M; Ota S; Matsubara H
    Ann Surg Oncol; 2019 Jun; 26(6):1805-1813. PubMed ID: 30977014
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis.
    Wang Y; Cheng X; Cui YH; Hou J; Ji Y; Sun YH; Shen ZB; Liu FL; Liu TS
    BMC Cancer; 2018 Jun; 18(1):702. PubMed ID: 29954358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Neoadjuvant Chemotherapy Combined with Adjuvant Chemotherapy for Locally Advanced Colon Cancer: A Propensity Score-Matching Analysis.
    Zeng W; Liu Y; Wang C; Yang C; Lin S; Li W
    Medicina (Kaunas); 2022 Oct; 58(11):. PubMed ID: 36363462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy Versus Chemotherapy Plus Chemoradiation as Neoadjuvant Therapy for Resectable Gastric Adenocarcinoma: A Multi-institutional Analysis.
    Allen CJ; Pointer DT; Blumenthaler AN; Mehta RJ; Hoffe SE; Minsky BD; Smith GL; Blum M; Mansfield PF; Ikoma N; Das P; Ajani J; Dineen SP; Fleming JB; Badgwell BD; Pimiento JM
    Ann Surg; 2021 Oct; 274(4):544-548. PubMed ID: 34132693
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of indocyanine green tracer-guided lymphadenectomy in laparoscopic gastrectomy after neoadjuvant chemotherapy for locally advanced gastric cancer: results from a multicenter analysis based on propensity matching.
    Huang ZN; Su-Yan ; Qiu WW; Liu CH; Chen QY; Zheng CH; Li P; Wang JB; Lin JX; Lu J; Cao LL; Lin M; Tu RH; Lin JL; Zheng HL; Lin GT; Huang CM
    Gastric Cancer; 2021 Nov; 24(6):1355-1364. PubMed ID: 34387763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of short- and long-term outcomes between laparoscopic and open gastrectomy for locally advanced gastric cancer following neoadjuvant chemotherapy: a propensity score matching analysis.
    Zhong H; Liu X; Tian Y; Cao S; Li Z; Liu G; Sun Y; Zhang X; Han Z; Meng C; Jia Z; Wang Q; Zhou Y
    Surg Endosc; 2023 Aug; 37(8):5902-5915. PubMed ID: 37072637
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of Adjuvant Chemotherapy With Overall Survival Among Patients With Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy.
    Lin JX; Tang YH; Lin GJ; Ma YB; Desiderio J; Li P; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu RH; Zheng CH; Parisi A; Truty MJ; Huang CM
    JAMA Netw Open; 2022 Apr; 5(4):e225557. PubMed ID: 35363268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer.
    Kosaka T; Akiyama H; Miyamoto H; Sato S; Tanaka Y; Sato K; Kunisaki C; Endo I
    Cancer Chemother Pharmacol; 2019 Jun; 83(6):1047-1055. PubMed ID: 30911769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant Chemotherapy
    Xu W; Wang L; Yan C; He C; Lu S; Ni Z; Hua Z; Zhu Z; Sah BK; Yang Z; Zheng Y; Feng R; Li C; Yao X; Chen M; Liu W; Yan M; Zhu Z
    Front Oncol; 2021; 11():718556. PubMed ID: 34497768
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathological response and outcome after neoadjuvant chemotherapy with DOC (docetaxel, oxaliplatin, capecitabine) or EOF (epirubicin, oxaliplatin, 5-fluorouracil) for clinical T3-T4 non-metastatic gastric cancer.
    Petrioli R; Marrelli D; Roviello F; D'Ignazio A; Torre P; Chirra M; Savelli V; Ambrosio MR; Francini G; Calomino N; Farsi M; Vernillo R; Francini E
    Surg Oncol; 2020 Mar; 32():2-7. PubMed ID: 31670056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Docetaxel + Oxaliplatin + S-1 vs Oxalipatin + S-1 as Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Propensity Score Matched Analysis.
    Zhang X; Huang H; Wei Z; Zhu Z; Yang D; Fu H; Xu J; Hu Z; Zhang Y; You Q; Huang X; Yan R; Wang W; Cai Q
    Cancer Manag Res; 2020; 12():6641-6653. PubMed ID: 32801898
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant Intraperitoneal and Systemic Chemotherapy Versus Neoadjuvant Systemic Chemotherapy With Docetaxel, Oxaliplatin, and S-1 for Gastric Cancer With Peritoneal Metastasis: A Propensity Score Matched Analysis.
    Zhang X; Huang H; Yang D; Wang P; Huang X; Hu Z; Zhang Y; Yan R; Zhu Z; Cai Q
    Technol Cancer Res Treat; 2021; 20():15330338211036310. PubMed ID: 34328799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.